CARIS LIFE SCIENCES INC (CAI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CAI • US1421521071

22.39 USD
+0.39 (+1.77%)
Last: Feb 9, 2026, 03:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, CAI scores 3 out of 10 in our fundamental rating. CAI was compared to 523 industry peers in the Biotechnology industry. CAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CAI has reported negative net income.
CAI Yearly Net Income VS EBIT VS OCF VS FCFCAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

  • The Return On Assets of CAI (-101.38%) is worse than 74.95% of its industry peers.
  • CAI's Return On Equity of -208.66% is on the low side compared to the rest of the industry. CAI is outperformed by 68.64% of its industry peers.
Industry RankSector Rank
ROA -101.38%
ROE -208.66%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CAI Yearly ROA, ROE, ROICCAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • With a decent Gross Margin value of 53.54%, CAI is doing good in the industry, outperforming 76.29% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for CAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAI Yearly Profit, Operating, Gross MarginsCAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CAI remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, CAI has more shares outstanding
  • Compared to 1 year ago, CAI has a worse debt to assets ratio.
CAI Yearly Shares OutstandingCAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2023 2024 50M 100M 150M 200M 250M
CAI Yearly Total Debt VS Total AssetsCAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2023 2024 1B 2B 3B

2.2 Solvency

  • CAI has an Altman-Z score of 4.49. This indicates that CAI is financially healthy and has little risk of bankruptcy at the moment.
  • CAI's Altman-Z score of 4.49 is fine compared to the rest of the industry. CAI outperforms 72.66% of its industry peers.
  • A Debt/Equity ratio of 0.79 indicates that CAI is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.79, CAI is doing worse than 72.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 4.49
ROIC/WACCN/A
WACC12.79%
CAI Yearly LT Debt VS Equity VS FCFCAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • CAI has a Current Ratio of 9.93. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CAI (9.93) is better than 81.07% of its industry peers.
  • CAI has a Quick Ratio of 9.36. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 9.36, CAI is doing good in the industry, outperforming 79.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.93
Quick Ratio 9.36
CAI Yearly Current Assets VS Current LiabilitesCAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
  • The Revenue has grown by 34.67% in the past year. This is a very strong growth!
  • Measured over the past years, CAI shows a small growth in Revenue. The Revenue has been growing by 6.64% on average per year.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A

3.2 Future

  • CAI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -37.72% yearly.
  • The Revenue is expected to grow by 30.63% on average over the next years. This is a very strong growth
EPS Next Y-131.19%
EPS Next 2Y-83.62%
EPS Next 3Y-58.31%
EPS Next 5Y-37.72%
Revenue Next Year80.21%
Revenue Next 2Y55.09%
Revenue Next 3Y43.23%
Revenue Next 5Y30.63%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAI Yearly Revenue VS EstimatesCAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
CAI Yearly EPS VS EstimatesCAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 119.18 indicates a quite expensive valuation of CAI.
  • CAI's Price/Forward Earnings ratio is rather cheap when compared to the industry. CAI is cheaper than 87.95% of the companies in the same industry.
  • CAI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.77.
Industry RankSector Rank
PE N/A
Fwd PE 119.18
CAI Price Earnings VS Forward Price EarningsCAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAI Per share dataCAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A cheap valuation may be justified as CAI's earnings are expected to decrease with -58.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.62%
EPS Next 3Y-58.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CARIS LIFE SCIENCES INC

NASDAQ:CAI (2/9/2026, 3:24:47 PM)

22.39

+0.39 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)N/A
Inst Owners37.15%
Inst Owner Change1.91%
Ins Owners48.47%
Ins Owner Change-1.33%
Market Cap6.32B
Revenue(TTM)931.41M
Net Income(TTM)-998.17M
Analysts84.62
Price Target38.65 (72.62%)
Short Float %5.68%
Short Ratio2.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1853.44%
Min EPS beat(2)-3845.54%
Max EPS beat(2)138.66%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)28.77%
Min Revenue beat(2)26.17%
Max Revenue beat(2)31.38%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.59%
PT rev (3m)-3.16%
EPS NQ rev (1m)98.1%
EPS NQ rev (3m)98.65%
EPS NY rev (1m)4.23%
EPS NY rev (3m)14.45%
Revenue NQ rev (1m)4.63%
Revenue NQ rev (3m)5.49%
Revenue NY rev (1m)2.31%
Revenue NY rev (3m)10.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 119.18
P/S 6.78
P/FCF N/A
P/OCF N/A
P/B 13.21
P/tB 13.76
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)0.19
Fwd EY0.84%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.3
BVpS1.7
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.38%
ROE -208.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.93
Quick Ratio 9.36
Altman-Z 4.49
F-ScoreN/A
WACC12.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-131.19%
EPS Next 2Y-83.62%
EPS Next 3Y-58.31%
EPS Next 5Y-37.72%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year80.21%
Revenue Next 2Y55.09%
Revenue Next 3Y43.23%
Revenue Next 5Y30.63%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.54%
EBIT Next 3Y47.53%
EBIT Next 5Y29.85%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A

CARIS LIFE SCIENCES INC / CAI FAQ

What is the fundamental rating for CAI stock?

ChartMill assigns a fundamental rating of 3 / 10 to CAI.


Can you provide the valuation status for CARIS LIFE SCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Overvalued.


Can you provide the profitability details for CARIS LIFE SCIENCES INC?

CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CAI stock?

The Earnings per Share (EPS) of CARIS LIFE SCIENCES INC (CAI) is expected to decline by -131.19% in the next year.